Tuesday, 3 January 2017

New targeted therapies show promise for treating advanced GIST

Two early-phase clinical trials testing new targeted therapies for advanced gastrointestinal stromal tumors (GIST) have produced promising preliminary results. Although the findings are preliminary, Lee Helman, M.D., of NCI's Center for Cancer Research, said the drugs show substantial promise as a treatment for patients with GIST whose tumors stop responding to standard therapies.

The trial results were presented earlier this month at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics ConferenceExit Disclaimer in Munich.

Read more here.

No comments:

Post a Comment